Navigation Links
Installation of Next Generation Proton Therapy System Progressing Rapidly
Date:10/26/2010

LITTLETON, Mass., Oct. 26 /PRNewswire/ -- Still River Systems' groundbreaking proton therapy system is entering the final phase of installation at the Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine in St. Louis, MO, a National Cancer Institute (NCI) Comprehensive Cancer Center. The precision of proton therapy makes it an important treatment option for patients with cancer, as it spares the healthy tissue and results in far fewer short- and long-term treatment complications. This unique device houses a revolutionary proton source based on the world's first superconducting synchrocyclotron and provides a significant reduction in the size, cost and complexity of developing and operating a proton therapy center.

This next generation proton therapy system is installed in three simple phases, in a radiation therapy room comparable in surface to that of conventional radiotherapy systems. Phase 1 consists of rigging and mounting the accelerator gantry, which holds and positions the proton source with sub-millimeter accuracy.  Phase 2 includes assembling and installing the clinical environment which comprises the 6D robotic couch, the high-accuracy treatment gantry and its applicators, the 2D/3D imaging and positioning systems and the clinical software interfaces.  The third and final phase consists of the installation of the accelerator module.   "The execution of phases 1 and 2 of the first installation went very smoothly and we are targeting 2 months to complete them in future installations," explains Bill Alvord, Vice President of Operations.

The production accelerator is now undergoing clinical commissioning, and all clinical parameters have exceeded performance expectations.  "The innovative design of our proton therapy system is simple and modular thus ensuring a lean and fast production line followed by a quick and efficient system installation," states CEO Joseph Jachinowski. "With our first system produced and its installation nearing completion, we are now reaping the benefits of its unique design by finalizing a complete process that can be replicated to meet the growing proton therapy demand."

Still River Systems will be exhibiting at the 52nd Annual Meeting of the American Society for Radiation Oncology in San Diego California on October 31st through November 3rd.  

ABOUT STILL RIVER SYSTEMS

Still River Systems, Inc., based in Littleton, Massachusetts, is dedicated to providing physicians, and their patients, access to high quality, cost-effective proton therapy solutions. Still River Systems is developing the Monarch250, an affordable, precise and compact proton therapy system for cancer treatment.

The Monarch250 has not been cleared by the US Food and Drug Administration for distribution or clinical use. For more information on Still River Systems and the Monarch250 Proton Therapy System, please call 978-540-1500 or visit www.stillriversystems.com


'/>"/>
SOURCE Still River Systems
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. New TROY SecureRx Prescription Printer Marks 50th Hospital Installation Milestone
2. Heska Announces First Installation of New Blood Gas & Electrolyte Analyzer
3. Health Robotics Surpasses 100 Installations Milestone and Acquires Two I.V. Room of the Future Partner Companies
4. Low Installation Rates in Retail Pharmacies Across Europe Increase the Growth Potential of the Pharmacy Automation Systems Market, Finds Frost & Sullivan
5. Althea Technologies Announces the Installation of a High-Speed Prefilled Syringe Line
6. Abbott and AstraZeneca Announce Selection of Next-Generation Fenofibrate ABT-335 and CRESTOR(R) Fixed-Dose Combination
7. Kosans Second-Generation Hsp90 Inhibitor, Alvespimycin, Shows 42% Clinical Benefit in Phase 1 HER2-Positive Metastatic Breast Cancer Trial
8. Beaumont Patients 1st to get Next Generation of Radiation Treatment
9. Boston Scientifics Next-Generation Stent Shows Improved Clinical Outcomes in Complex Lesions
10. BiPar Announces Preclinical Data Demonstrating Anti-Tumor Activity With BSI-401, Its Second-Generation PARP Inhibitor
11. Acologix Presents Preclinical Data on Cartilage Regeneration by AC-100 at the OARSI 2007 World Congress on Osteoarthritis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... , Dec. 8, 2016 Eli Lilly and ... the neoMONARCH study of abemaciclib, a cyclin-dependent kinase (CDK) ... of reducing expression of Ki67, a biomarker of cell ... the Phase 2 trial presented during the official press ... (SABCS) evaluated abemaciclib, both alone or in combination with ...
(Date:12/7/2016)... Global Cervical Dysplasia Market: Scope and ... dysplasia market analyzes the current and future prospects ... executive summary, including a market snapshot that provides ... The research is a combination of primary and ... our research efforts along with information collected from ...
(Date:12/7/2016)... REPORT OBJECTIVES The report ... intelligence on a market segment, based on geography. ... in the report. The primary objectives of this ... intelligence through detailed segmentation, 2) market size and ... developments, market situation, trends, 3) detailed analysis of ...
Breaking Medicine Technology:
(Date:12/8/2016)... ... 2016 , ... Healthcare is in flux. The GOP wants ... mass media launching of story movements to highlight what's most unfair about healthcare. ... such a movement can generate the network power to improve healthcare policies in ...
(Date:12/8/2016)... ... December 08, 2016 , ... ... that serve communities in and around the greater Phoenix metropolitan region, is announcing ... Connection. , The mission of the Homeless Youth Connection is to promote community ...
(Date:12/7/2016)... PA (PRWEB) , ... December 07, 2016 , ... ... with the announcement that it is one of the early adopters completing EU-U.S. Privacy ... Framework is designed to provide companies on both sides of the Atlantic with a ...
(Date:12/7/2016)... ... December 07, 2016 , ... ... wrinkles and deep lines by smoothing and tightening the skin of the face ... there to address facial aging with very little downtime, Silhouette Instalift is a ...
(Date:12/7/2016)... ... December 07, 2016 , ... It is vital for any lab to secure ... data. The team at Beckman Coulter has designed Kaluza, templates with advanced analytical tools ... need to operate in a GLP (Good Laboratory Practice) fashion. , With features designed ...
Breaking Medicine News(10 mins):